Skip to main content
SpringerLink
Log in

The Development of Epstein-Barr Virus Vaccines

  • Chapter
DNA Tumor Viruses

Part of the book series: Infectious Agents and Pathogenesis ((IAPA))

Abstract

Epstein-Barr virus (EBV) is one of the handful of human herpesviruses and is of great significance because of its oncogenic potential in humans [reviewed by Liebowitz and Kieff(1,2) and Miller(3)]. Infection with EBV usually occurs in early childhood with no clinical consequences, and humoral and cell-mediated immune responses develop that control virus replication and the number of infected cells present in the individual. The growing number of clinical conditions, including Burkitt’s lymphoma (BL) and nasopharyngeal carcinoma (NPC), now associated with this virus has warranted the development of vaccines to prevent or modify EBV infection, a thesis first articulated by M. A. Epstein in 1976.(4)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Liebowitz, D., and Kieff, E., 1990, Replication of Epstein-Barr virus, in: Fields Virology (B. Fields and D. Knipe, eds.), Raven Press, New York, pp. 1889–1920.

    Google Scholar 

  2. Liebowitz, D., and Kieff, E., 1993, Epstein-Barr virus, in: The Human Herpesviruses (B. Roizman, R. J. Whitley, and C. Lopez, eds.), Raven Press, New York, pp. 107–172.

    Google Scholar 

  3. Miller, G., 1990, The Epstein-Barr virus, in: Fields Virology, (B. Fields and D. Knipe, eds.), Raven Press, New York, pp. 1921–1958.

    Google Scholar 

  4. Epstein, M. A., 1976, Epstein-Barr virus–Is it time to develop a vaccine program? J. Natl. Cancer Inst. 56:697–700.

    PubMed  CAS  Google Scholar 

  5. Tanner, J., Whang, Y., Sample, J., Sears, A., and Kieff, E., 1988, Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes, J. Virol. 62:4452–4464.

    PubMed  CAS  Google Scholar 

  6. Moore, M. D., DiScipio, R. G., Cooper, N. R., and Nemerow, G. R., 1989, Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2), J. Biol Chem. 264:20576–20582.

    PubMed  CAS  Google Scholar 

  7. Birkenbach, M., Tong, X., Bradbury, L. E., Tedder, T., and Kieff, E., 1992, Characterization of an Epstein-Barr virus receptor on human epithelial cells, J. Exp. Med. 176:1405–1414.

    Article  PubMed  CAS  Google Scholar 

  8. Sixbey, J. W., Vesterinen, E. H., Nedrud, J. G., Raab-Traub, N., Walton, L. A., and Pagano, J. S., 1983, Replication of Epstein-Barr virus in human epithelial cells infected in vitro, Nature 306:480–483.

    Article  PubMed  CAS  Google Scholar 

  9. Sixbey, J. W., Nedrud, J. G., Raab-Traub, N., Hanes, R. A., and Pagano, J. S., 1984, Epstein-Barr virus replication in oropharyngeal epithelial cells, N. Engl. J. Med. 310:1225–1230.

    Article  PubMed  CAS  Google Scholar 

  10. Sixbey, J. W., Lemon, S. M., and Pagano, J. S., 1986, A second site for Epstein-Barr virus shedding: The uterine cervix, Lancet 2:1122–1124.

    Article  PubMed  CAS  Google Scholar 

  11. Israele, V., Shirley, P., and Sixbey, J. W., 1991, Excretion of the Epstein-Barr virus from the genital tract of men, J. Infect. Dis. 163:1341–1343.

    Article  PubMed  CAS  Google Scholar 

  12. Tosato, G., and Blaese, R. M., 1985, Epstein-Barr virus infection and immunoregulation in man, Adv. Immunol. 37:99–149.

    Article  PubMed  CAS  Google Scholar 

  13. Rickinson, A. B., Gregory, C. D., Murray, R. J., Ulaeto, D. O., and Rowe, M., 1989, Cell mediated immunity to Epstein-Barr virus and the pathogenesis of virus-associated B cell lymphomas, in: Immune Responses, Virus Infections and Disease (N.J. Dimmock and P. D. Minor, eds.), IRL Press, Oxford, pp. 59–83.

    Google Scholar 

  14. Khanna, R., Burrows, S. R., Kurilla, M. G. Jacob, C. A., Misko, I. S., Sculley, T. B., Kieff, E., and Moss, D. J., 1992, Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development, J. Exp. Med. 176:169–176.

    Article  PubMed  CAS  Google Scholar 

  15. Murray, R. J., Kurilla, M. G., Brooks, J. M., Thomas, W. A., Rowe, M., Kieff, E., and Rickinson, A. B., 1992, Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies, J. Exp. Med. 176:157–168.

    Article  PubMed  CAS  Google Scholar 

  16. Zimber U., Adldinger H. K., Lenoir G. M., Vuillaume, M., Knebel-Doeberitz, M. V., Laux, G., Desgranges, C., Wittmann, P., Freese, U. K., and Schneider, U., 1986, Geographical prevalence of two types of Epstein-Barr virus. Virology 154:56–66.

    Article  PubMed  CAS  Google Scholar 

  17. Sample, J., Young, L., Martin, B., Chatmou, T., Kieff, E., Rickinson, A., and Kieff, E., 1990, Epstein-Barr virus types 1 and 2 differ in their BNA-3a, EBNA-3b, and EBNA-3c genes, J. Virol. 64:4084–4092.

    PubMed  CAS  Google Scholar 

  18. Gratama, J. W., Oosterveer, M. A., Lepoutre J. M., Van Rood, J. J., Zwaan, F. E., Vossen, J. M., Kapsenberg, J. G., Richel, D., Klein, G., and Ernberg, I., 1990, Serological and molecular studies of Epstein-Barr virus infection in allogeneic marrow graft recipients, Transplantation 49:725–730.

    Article  PubMed  CAS  Google Scholar 

  19. Epstein, M. A., Achong, B. G., and Barr, Y. M., 1964, Virus particles in cultured lymphoblasts from Burkitt’s lymphoma, Lancet 1:702–703.

    Article  PubMed  CAS  Google Scholar 

  20. Magrath, I., 1990, The pathogenesis of Burkitt’s lymphoma, Adv. Cancer Res. 55:133–270.

    Article  PubMed  CAS  Google Scholar 

  21. Cleary, M. L., Epstein, M. A., Finerty, S., Dorfman, R. F., Bornkamm, G. W., Kirkwood, J. K., Morgan, A. J., and Sklar, J., 1985, Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones, Science 228:722–724.

    Article  PubMed  CAS  Google Scholar 

  22. Miller, G., Shope, T., Coope, D., Waters, L., Pagano, J., Bornkamm, G. W., and Henlé, W., 1977, Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: Tumor incidence, histologic spectrum, antibody responses, demonstration of viral DNA, and characterization of viruses. J. Exp. Med. 145:948–967.

    Article  PubMed  CAS  Google Scholar 

  23. Miller, G., 1979, Experimental carcinogenicity by the virus in vivo, in: The Epstein-Barr Virus (M. A. Epstein and B. G. Achong, eds.), Springer, Berlin, pp. 351–372.

    Chapter  Google Scholar 

  24. Shope, T., Dechairo, D., and Miller, G., 1973, Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus, Proc. Natl. Acad. Sci. USA 70:2487–2491.

    Article  PubMed  CAS  Google Scholar 

  25. Henlé, W., Henlé, G., Ho, H.-C., Burtin, P., Cachin, Y., Clifford, P., de Schryver, A., de-Thé, G., Diehl, V., and Klein, G., 1970, Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups, J. Natl. Cancer Inst. 44:225–231.

    PubMed  Google Scholar 

  26. Zur Hausen, H., Schulte-Holthausen, H., Klein, G., Henlé, W., Henlé, G., Clifford, P., and Santesson, L., 1970, EBV DNA in biopsies of Burkitt tumors and anaplastic carcinomas of the nasopharynx, Nature 228:1056–1058.

    Article  PubMed  Google Scholar 

  27. Zeng, Y, 1985, Seroepidemiological studies on nasopharyngeal carcinoma in China, Adv. Cancer Res. 44:121–138.

    Article  PubMed  CAS  Google Scholar 

  28. Parkin, D. M., Stjemsward, J., and Muir, C. S., 1984, Estimates for the worldwide frequency of twelve major cancers, Bull. WHO 62:163–182.

    PubMed  CAS  Google Scholar 

  29. Herbst, H., Niedobitek, G., Kneba, M., Hummel, M., Finn, T., Anagnostopoulos, I., Bergholz, M., Krieger, G., and Stein, H., 1990, High incidence of Epstein-Barr virus genomes in Hodgkin’s disease, Am. J. Pathol. 137:13–18.

    PubMed  CAS  Google Scholar 

  30. Herbst, H., Stein, H., and Niedobitek, G., 1993, Epstein-Barr virus and CD30+ malignant lymphomas, Crit. Rev. Oncol. 4:191–239.

    CAS  Google Scholar 

  31. Pallesen, G., Hamilton Dutoit, S. J., Rowe, M., and Young, L. S., 1991, Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s disease, Lancet 337:320–322.

    Article  PubMed  CAS  Google Scholar 

  32. Stein, H., Herbst, H., Anagnostopoulos, I., Niedobitek, G., Dallenbach, F., and Kratzsch, H. C., 1991, The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma, Ann. Oncol. 2:33–38.

    Article  PubMed  Google Scholar 

  33. Wu, T. C., Mann, R. B., Charache, P., Hayward, S. D., Staal, S., Lambe, B., and Ambinder, R. F., 1990, Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin’s disease, Int. J. Cancer 46:801–804.

    Article  PubMed  CAS  Google Scholar 

  34. Ambinder, R. E., Browning, P. J., Lorenzana, I., Leventhal, B. G., Cosenza, H., Mann, R. B., MacMahon, E. M., Medina, R., Cardona, V., and Grufferman, S., 1993, Epstein-Barr virus and childhood Hodgkin’s disease in Honduras and the United States, Blood 81:462–467.

    PubMed  CAS  Google Scholar 

  35. Mueller, N., Evans, A., Harris, N. L., Comstock, G. W., Jellum, E., Magnus, K., Orentreich, N., Polk, B. F., and Vogelman, J., 1989, Hodgkin’s disease and Epstein-Barr virus. Altered antibody pattern before diagnosis, N. Engl. J. Med. 320:689–695.

    Article  PubMed  CAS  Google Scholar 

  36. Hanto, D. W., Frizzera, G., Gajl-Peczalska, K.J., Sakamoto, K., Purtilo, D. T., Balfour, H. H., Jr., Simmons, R. L., and Najarian, J. S., 1982, Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation, N. Engl. J. Med. 306:913–918.

    Article  PubMed  CAS  Google Scholar 

  37. Purtilo, D. T., Tatsumi, E., Manolov, G., Manolova, Y., Harada, S., Lipscomb, H., and Krueger, G., 1985, Epstein-Barr virus as an etiological agent in the pathogenesis of lymphoproliferative and aproliferative diseases in immune deficient patients, Int. Rev. Exp. Pathol. 27:113–183.

    PubMed  CAS  Google Scholar 

  38. Thomas, J. A., and Crawford, D. H., 1989, Epstein-Barr virus associated B-cell lymphomas in AIDS and after organ transplantation, Lancet 1:1075–1076.

    Article  PubMed  CAS  Google Scholar 

  39. Facer, C. A., and Playfair, J. H., 1989, Malaria, Epstein-Barr virus, and the genesis of lymphomas, Adv. Cancer Res. 53:33–72.

    Article  PubMed  CAS  Google Scholar 

  40. Whittle, H. C., Brown J., Marsh, K., Blackman, M., Jobe, O., and Shenton, F., 1990, The effects of Plasmodiumfalciparum malaria on immune control of B lymphocytes in Gambian children, Clin. Exp. Immunol. 80:213–218.

    Article  PubMed  CAS  Google Scholar 

  41. Whittle, H. C., Brown J., Marsh, K., Greenwood, B. M., Seidelin, P., Tighe, H., and Wedderburn, L., 1984, T-cell control of Epstein-Barr virus-infected B cells is lost during P.falciparum malaria, Nature 312:449–450.

    Article  PubMed  CAS  Google Scholar 

  42. Chen, C.J., Liang, K. Y., Chang, Y S., Wang, Y. F., Hsieh, T., Hsu, M. M., Chen, J. Y., and Liu, M. Y, 1990, Multiple risk factors of nasopharyngeal carcinoma: Epstein-Barr virus, malarial infection, cigarette smoking and familial tendency, Anticancer Res. 10:547–553.

    PubMed  CAS  Google Scholar 

  43. Lu, S., Day, N. E., Degos, L., Lepage, V., Wang, P.-C., Chan, S.-H., Simons, M., McKnight, B., Easton, D., Zeng, Yi., and de-Thé, G., 1990, Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region, Nature 346:470–471.

    Article  PubMed  CAS  Google Scholar 

  44. Henlé, G., Henlé, W., and Diehl, V., 1968, Relation of Burkitt’s tumor-associated herpes-type virus to infectious mononucleosis, Proc. Natl. Acad. Sci. USA 59:94–101.

    Article  PubMed  Google Scholar 

  45. Evans, A. S., 1993, Epstein-Barr vaccine: Use in infectious mononucleosis, in: The Epstein-Barr Virus and Associated Diseases (T. Tursz, J. S. Pagano, D. V., Ablashi, G. de Thé, G. Lenoir, and G. R. Pearson, eds.) J. Libbey, London/INSERM, Paris, pp. 593–598.

    Google Scholar 

  46. Burke, R. L., 1993, Current developments in HSV vaccines, Semin. Virol. 4:187–197.

    Article  CAS  Google Scholar 

  47. Kaaden, O. R., and Dietzschold, B., 1974, Alterations of the immunological specificity of plasma membranes of cells infected with Marek’s disease and turkey herpes viruses, J. Gen. Virol. 25:1–10.

    Article  PubMed  CAS  Google Scholar 

  48. Laufs, R., and Steinke, H., 1975, Vaccination of non-human primates against malignant lymphoma, Nature 253:71–72.

    Article  PubMed  CAS  Google Scholar 

  49. De Schryver, A., Klein, G., Hewetson, J., Rocchi, G., Henlé, W., Henlé, G., Moss, D. J., and Pope, J. H., 1974, Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti MA), Int. J. Cancer 13:353–362.

    Article  PubMed  Google Scholar 

  50. Pearson, G., Dewey, E., Klein, G., Henlé, G., and Henlé, W., 1970, Relation between neutralization of Epstein-Barr virus and antibodies to cell-membrane antigens induced by the virus, J. Natl. Cancer Inst. 45:989–995.

    PubMed  CAS  Google Scholar 

  51. Hoffman, G. J., Lazarowitz, S. G., and Hayward, S. D., 1980, Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen, Proc. Natl. Acad. Sci. USA 77:2979–2983.

    Article  PubMed  CAS  Google Scholar 

  52. North, J. R., Morgan, A. J., and Epstein, M. A., 1980, Observations on the EBV envelope and virus-determined membrane antigen (MA) polypeptides, Int. J. Cancer 26:231–240.

    Article  PubMed  CAS  Google Scholar 

  53. Qualtière, L. F., and Pearson, G. R., 1980, Radioimmune precipitation study comparing the Epstein-Barr virus membrane antigens expressed on P3HR-1 virus-superinfected Raji cells to those expressed on cells in a B95-8 virus-transformed producer culture activated with tumor-promoting agent (TPA), Virology 102:360–369.

    Article  PubMed  Google Scholar 

  54. Qualtière, L. E., and Pearson, G. R., 1979, Epstein-Barr virus-induced membrane antigens: Immunochemical characterisation of Triton X100 solubilized viral membrane antigens from EBV-superinfected Raji cells, Int. J. Cancer 23:808–817.

    Article  PubMed  Google Scholar 

  55. Thorley-Lawson, D. A., and Geilinger, K., 1980, Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity, Proc. Natl. Acad. Sci. USA 77:5307–5311.

    Article  PubMed  CAS  Google Scholar 

  56. Beisel, C., Tanner, J., Matsuo, T., Thorley-Lawson, D., Kezdy, F., and Kieff, E., 1985, Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene, J. Virol. 54:665–674.

    PubMed  CAS  Google Scholar 

  57. Haddad, R. S., and Hutt-Fletcher, L. M., 1989, Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells, J. Virol. 63:4998–5005.

    PubMed  CAS  Google Scholar 

  58. Heineman, T., Gong, M., Sample, J., and Kieff, E., 1988, Identification of the Epstein-Barr virus gp85 gene, J. Virol. 62:1101–1107.

    PubMed  CAS  Google Scholar 

  59. Miller, N., and Hutt-Fletcher, L. M., 1988, A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus, J. Virol. 62:2366–2372.

    PubMed  CAS  Google Scholar 

  60. North, J. R., Morgan, A. J., Thompson, J. L., and Epstein, M. A., 1982, Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes, Proc. Natl. Acad. Sci. USA 79:7504–7508.

    Article  PubMed  CAS  Google Scholar 

  61. Morgan, A. J., North, J. R., and Epstein, M. A., 1983, Purification and properties of the gp340 component of Epstein-Barr virus membrane antigen in an immunogenic form, J. Gen. Virol. 64:455–460.

    Article  PubMed  CAS  Google Scholar 

  62. Epstein, M. A., Morgan, A.J., Finerty, S., Randle, B.J., and Kirkwood, J. K., 1985, Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine, Nature 318:287–289.

    Article  PubMed  CAS  Google Scholar 

  63. Morgan, A. J., Smith, A. R., Barker, R. N., and Epstein, M. A., 1984, A structural investigation of the Epstein-Barr (EB) virus membrane antigen glycoprotein, gp340, J. Gen. Virol. 65:397–404.

    Article  PubMed  CAS  Google Scholar 

  64. Serafini-Cessi, F., Malagolini, N., Nanni, M., Dall’Olio, F., Campadelli-Fiume, G., Tanner, J., and Kieff, E., 1989, Characterization of N-and O-linked oligosaccharides of glycoprotein 350 from Epstein-Barr virus, Virology 170:1–10.

    Article  PubMed  CAS  Google Scholar 

  65. Lees, J. F., Arrand, J. E., Pepper, S. D., Stewart, J. P., Mackett, M., and Arrand, J. R., 1993, The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B, Virology 195:578–586.

    Article  PubMed  CAS  Google Scholar 

  66. Baer, R., Bankier, A. T., Biggin, M. D., Deininger, P. L., Farrell, P. J., Gibson, T. J., Hatfull, G., Hudson, G. S., Satchwell, S. C., Seguin, C., Tuffrrell, P. S., and Barrell, B. G., 1984, DNA sequence and expression of the B95-8 Epstein-Barr virus genome, Nature 310:207–211.

    Article  PubMed  CAS  Google Scholar 

  67. Gong, M., and Kieff, E., 1990, Intracellular trafficking of two major Epstein-Barr virus glycoproteins, gp350/220 and gp110, J. Virol. 64:1507–1516.

    PubMed  CAS  Google Scholar 

  68. Gong, M., Ooka, T., Matsuo, T., and Kieff, E., 1987, Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB, J. Virol. 61:499–508.

    PubMed  CAS  Google Scholar 

  69. Mackett, M., Conway, M. J., Arrand, J. R., Haddad, R. S., and Hutt-Fletcher, L. M., 1990, Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus BamHI I fragment, J. Virol. 64:2545–2552.

    PubMed  CAS  Google Scholar 

  70. Emini, E. A., Luka, J., Armstrong, M. E., Banker, F. S., Provost, P. J., and Pearson, G. R., 1986, Establishment and characterization of a chronic infectious mononucleosislike syndrome in common marmosets, J. Med. Virol. 18:369–379.

    Article  PubMed  CAS  Google Scholar 

  71. Wedderburn, N., Edwards, J. M. B., Desgranges, C., Fontaine, C., Cohen, B., de Thé, G., 1984, Infectious mononucleosis-like response in common marmosets infected with Epstein-Barr virus, J. Infect. Dis. 150:878–882.

    Article  PubMed  CAS  Google Scholar 

  72. Ma, N. S. F., 1981, Chromosome evolution in the owl monkey, Aotus, Am.J. Phys. Anthropol. 54:293–303.

    Article  Google Scholar 

  73. Young, L. S., Finerty, S., Brooks, L., Scullion, E., Rickinson, A. B., and Morgan, A. J., 1989, Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of the cottontop tamarin, J. Virol. 63:1967–1974.

    PubMed  CAS  Google Scholar 

  74. Watkins, D. I., Hodi, F. S., and Letvin, N. L., 1988, A primate species with a limited major histocompability complex class I polymorphism, Proc. Natl. Acad. Sci. USA 85:7714–7718.

    Article  PubMed  CAS  Google Scholar 

  75. Niedobitek, G., Agathanggelou, A., Finerty, S., Tierney, R., Jones, E. L., Watkins, P., Morgan, A. J., Young, L. S., and Rooney, N., 1994, Latent Epstein-Barr virus infection in cottontop tamarins: A possible model for EBV infection in humans, Am. J. Pathol. 145:969–978.

    PubMed  CAS  Google Scholar 

  76. Epstein, M. A., Randle, B. J., Finerty, S., and Kirkwood, J. K., 1986, Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals, Clin. Exp. Immunol. 63:485–490.

    PubMed  CAS  Google Scholar 

  77. David, E. M., and Morgan, A. J., 1988, Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography, J. Immunol. Methods 108:231–236.

    Article  PubMed  CAS  Google Scholar 

  78. Morein, B., Sundquist, B., Hoglund, S., Dalsgaard, K., and Osterhaus, A., 1984, ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses, Nature 308:457–460.

    Article  PubMed  CAS  Google Scholar 

  79. Morgan, A. J., Finerty, S., Lovgren, K., Scullion, F. T., and Morein, B., 1988, Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes, J. Gen. Virol. 69:2093–2096.

    Article  PubMed  CAS  Google Scholar 

  80. Allison, A. C., and Byers, N. E., 1986, An adjuvant formulation that selectively elicits the formation of antibodies of protective isotype and cell-mediated immunity, J. Immunol. Methods 95:157–168.

    Article  PubMed  CAS  Google Scholar 

  81. Morgan, A. J., Allison, A. C., Finerty, S., Scullion, F. T., Byars, N. E., and Epstein, M. A., 1989, Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use, J. Med. Virol. 29:74–78.

    Article  PubMed  CAS  Google Scholar 

  82. Pither, R. J., Zhang, C. X., Wallace, L. E., Rickinson, A. B., and Morgan, A. J., 1991, Mapping of B and T cell epitopes on the Epstein-Barr major envelope glycoprotein gp340, in: Vaccines 91 (R. A. Lerner, H. Ginsberg, R. M. Chanock, and F. Brown, eds.), Cold Spring Harbor, New York, pp. 197–201.

    Google Scholar 

  83. Pither, R. J., Nolan, L., Tarlton, J., Walford, J., and Morgan, A. J., 1992, Distribution of epitopes within the amino acid sequence of the Epstein-Barr virus major envelope glycoprotein, gp340, recognized by hyperimmune rabbit sera, J. Gen. Virol. 73:1409–1415.

    Article  PubMed  CAS  Google Scholar 

  84. Pither, R.J., Zhang, C. X., Shiels, C., Tarlton J., Finerty, S., and Morgan, A.J., 1992, Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340, J. Virol. 66:1246–1251.

    PubMed  CAS  Google Scholar 

  85. Pither, R. J., Zhang, C. X., Wallace, L. E., Rickinson, A. B., and Morgan, A. J., 1991, Mapping of B and T cell epitopes on the Epstein-Barr receptor ligand gp340: A candidate subunit vaccine, in: Epstein-Barr Virus and Human Disease 1990 (D. V. Ablashi, A. T. Huang, A. S. Pagano, J. R. Pearson, and C. S. Yang, eds.) Humana, Clifton, New Jersey, pp. 207–211.

    Chapter  Google Scholar 

  86. Zhang, P. F., Klutch, M., Armstrong, G., Qualtiere, L., Pearson, G., and Marcus-Sekura, C. J., 1991, Mapping of the epitopes of Epstein-Barr virus gp350 using monoclonal antibodies and recombinant proteins expressed in Escherichia coli defines three antigenic determinants, J. Gen. Virol 72:2747–2755.

    Article  PubMed  CAS  Google Scholar 

  87. Schultz, L. D., Tanner J., Hofmann, K.J., Emini, E. A., Condra, J. H. Jones, R. E., Kieff, E., and Ellis, R. W., 1987, Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus, Gene 54:113–123.

    Article  PubMed  CAS  Google Scholar 

  88. Emini, E. A., Schleif, W. A., Armstrong, M. E., Silberklang, M., Schultz, L. D., Lehman, D., Maigetter, R. Z., Qualtiere, L. F., Pearson, G. R., and Ellis, R. W., 1987 Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: Implications for the development of a subunit vaccine, Virology 166:387–393.

    Article  Google Scholar 

  89. Nuebling, C. M., Buck, M., Boos, H., von Deimling, A., and Mueller Lantzsch, N., 1992, Expression of Epstein-Barr virus membrane antigen gp350/220 in E. coli and in insect cells, Virology 191:443–447.

    Article  PubMed  CAS  Google Scholar 

  90. Conway, M., Morgan, A. J., and Mackett, M., 1988, Expression of Epstein-Barr virus membrane antigen gp340/220 in mouse fibroblasts using a bovine papilloma virus vector, J. Gen. Virol. 70:729–734.

    Article  Google Scholar 

  91. Hessing, M., van Schijndel, H. B., van Grunsven, W. M., Wolf, H., and Middeldorp, J., 1992, Purification and quantification of recombinant Epstein-Barr viral glycoproteins gp350/220 from Chinese hamster ovary cells, J. Chromatogr. 599:267–272.

    Article  PubMed  CAS  Google Scholar 

  92. Madej, M., Conway, M. J., Morgan, A. J., Sweet, J., Wallace, L., Arrand, J., and Mackett, M., 1992, Purification and characterisation of Epstein-Barr virus gp340/220 produced by a bovine papilloma virus vector system, Vaccine 10:777–782.

    Article  PubMed  CAS  Google Scholar 

  93. Motz, M., Deby, G., Jilg, W., and Wolf, H., 1986, Expression of the Epstein-Barr virus major membrane proteins in Chinese hamster ovary cells, Gene 44:353–359.

    Article  PubMed  CAS  Google Scholar 

  94. Whang, Y., Silberklang, M., Morgan, A., Munshi, S., Lenny, A. B., Ellis, R. W., and Kieff, E., 1987, Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells, J. Virol. 61:1796–1807.

    PubMed  CAS  Google Scholar 

  95. Ulaeto, D., Wallace, L., Morgan, A. J., Morein, B., and Rickinson, A. B., 1988, In vitro T cell responses to a candidate Epstein-Barr virus vaccine: Human CD4+ T-cell clones specific for the major envelope glycoprotein gp340, Eur. J. Immunol. 18:1689–1697.

    Article  PubMed  CAS  Google Scholar 

  96. Wallace, L. E., Wright, J., Ulaeto, D. O., Morgan, A. J., and Rickinson, A. B., 1991, Identification of two T-cell epitopes of the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CF4+ T-cell clones, J. Virol. 65:3821–3828.

    PubMed  CAS  Google Scholar 

  97. Carter, M. J., Facklam, T. J., Long, P. C., and Scotland, R. A., 1988, Are continuous cell lines safe as substrates for human drugs and biologies? A case study with human growth hormone, Dev. Biol. Stand. 70:101–107.

    Google Scholar 

  98. Mossman, T. R., and Coffman, R. L., 1989, Heterogeneity of cytokine secretion patterns and functions of helper T cells, Adv. Immunol. 46:111–147.

    Article  Google Scholar 

  99. Afonso, L. C. C., Scharton, T. M., Vieira, L. Q., Wysocka, M., Trinchieri, G., and Scott, P., 1994, The adjuvant effect of interleukin-12 against Leishmania major, Science 263:235–237.

    CAS  Google Scholar 

  100. Finerty, S., Tarlton, J., Mackett, M., Conway, M., Arrand, J. R., Watkins, P. E., and Morgan, A. J., 1992, Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector, J. Gen. Virol. 73:449–453.

    Article  PubMed  CAS  Google Scholar 

  101. Finerty, S., Mackett, M., Arrand, J. R., Watkins, P. E., Tarlton, J., and Morgan, A. J., 1994, Immunisation of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum, Vaccine 12:1180–1184.

    Article  PubMed  CAS  Google Scholar 

  102. Emini, E. A., Schleif, W. A., Silberklang, M., Lehman, D., and Ellis, R. W., 1989, Vero cell-expressed Epstein-Barr virus (EBV) gp350/220 protects marmosets from EBV challenge, J. Med. Virol. 27:120–123.

    Article  PubMed  CAS  Google Scholar 

  103. Murphy, F. A., 1989, Vaccinia-vectored vaccines, risks and benefits, Res. Virol. 140:463–491.

    Article  PubMed  CAS  Google Scholar 

  104. Takahashi, H., Takeshita, T., Morein, B., Putney, S., Germain, R. N., and Berzofsky, J. A., 1990, Induction of CD8+ cytotoxic T cells glycoprotein by immunisation with purified HIV-1 envelope protein in ISCOMS, Nature 344:873–875.

    Article  PubMed  CAS  Google Scholar 

  105. Byars, N. E., Nakano, G., Welch, M., Lehman, D., and Allison, A. C., 1991, Improvement of hepatitis B vaccine by the use of a new adjuvant, Vaccine 9:309–318.

    Article  PubMed  CAS  Google Scholar 

  106. Dillon, S. B., Demuth, S. G., Schneider, M. A., Weston, C. B. Jones, C. S., Young, J. F., Scott, M., Bhatnaghar, S., LoCastro, S., and Hanna, N., 1992, Induction of Class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant, Vaccine 10:309–318.

    Article  PubMed  CAS  Google Scholar 

  107. Murphy, R., and Chanock, R. M., 1990, Immunisation against viruses, in: Fields Virology (B. Fields and D. Knipe, eds.), Raven Press, New York, pp. 469–502.

    Google Scholar 

  108. Brochier, B., Languet, B., Blancou, J., Thomas, I., Kieny, M. P., Costy, F., Desmettre, P., and Pastoret, P.-P., 1989, Use of recombinant vaccinia-rabies virus for oral protection of wildlife against rabies: Inocuity to several non target bait-consuming species, J. Wildl. Dis. 25:540.

    PubMed  CAS  Google Scholar 

  109. Mackett, M., and Arrand, J. A., 1985, Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340, EMBO J. 4:3229–3234.

    PubMed  CAS  Google Scholar 

  110. Ragot, T., Finerty, S., Watkins, P. E., Perricaudet, M., and Morgan, A. J., 1993, Replicationdefective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin, J. Gen. Virol. 74:501–507.

    Article  PubMed  CAS  Google Scholar 

  111. Lowe, R. S., Keller, P. M., Keech, B. Y., Davison, A. J., Whang, Y., Morgan, A. J., Kieff, E., and Ellis, R. W., 1987, Varicella zoster virus as a live vector for the expression of foreign genes, Proc. Natl. Acad. Sci. USA 84:3896–3900.

    Article  PubMed  CAS  Google Scholar 

  112. Taylor, J., Weinberg, R., Tartaglia, J., Richardson, C., Alkhatib, G., Briedis, D., Appel, M., Norton, E., and Paoletti, E., 1992, Nonreplicating viral vectors as potential vaccines, recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins, Virology 187:321–328.

    Article  PubMed  CAS  Google Scholar 

  113. Tartaglia, J., Perkus, M. E., Taylor, J., Norton, E. K., Audonnet, J.-C., Cox, W I., Davis, S. W., Van der Hoeven, J., Meignier, B., Riviere, M., Languet, B., and Paoletti, E., 1992, NYVAC: A highly attenuated strain of vaccinia virus, Virology 188:217–232.

    Article  PubMed  CAS  Google Scholar 

  114. Morgan, A. J., Mackett, M., Finerty, S., Arrand, J. R., Scullion, F. T., and Epstein, M. A., 1988, Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EBV-induced malignant lymphomas, J. Med. Virol. 25:189–195.

    Article  PubMed  CAS  Google Scholar 

  115. Alkhatib, G., and Briedis, D. J., 1988, High level eucaryotic in vivo expression of biologically active measles virus haemagglutinin by using an adenovirus type 5 helper-free vector system, J. Virol. 62:2718–2727.

    PubMed  CAS  Google Scholar 

  116. Ballay, A., Levrero, M., Buendia, M. A., Tiollais, P., and Perricaudet, M., 1985, In vitro and in vivo synthesis of the hepatitis B surface antigen and of the receptor for polymerised human serum albumin from recombinant human adenovirus, EMBO J. 4:3861–3865.

    PubMed  CAS  Google Scholar 

  117. Dewar, R. L., Natarajan, V., Vasudevachari, M. B., and Salzman, N. P., 1989, Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus, J. Virol. 63:129–136.

    PubMed  CAS  Google Scholar 

  118. Eloit, M., Gilardi-Hebeystreit, P., Toma, B., and Perricaudet, M., 1990, Construction of a defective adenovirus expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine, J. Gen. Virol. 71:2425–2431.

    Article  PubMed  CAS  Google Scholar 

  119. Johnson, D. C., Ghosh-Choudery, G., Smiley, J. R., Fallis, L., and Graham, F. L., 1988, Abundant expression of herpes simplex virus glycoprotein gB using an adenovirus vector, Virology 164:1–14.

    Article  PubMed  CAS  Google Scholar 

  120. Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R., 1977, Characteristics of a human cell line transformed by DNA from human adenovirus type 5, J. Gen. Virol. 36:59–72.

    Article  PubMed  CAS  Google Scholar 

  121. Top, F. H., Jr., Grossman, R. A., Bartelloni, P.J., Segal, H. E., Dudding, B. A., Russell, P. K., and Büscher, E. L., 1971, Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans, J. Infect. Dis. 124:148–154.

    Article  PubMed  Google Scholar 

  122. Top, F. H., Jr., Büscher, E. L., Bancroft, W. H., and Russell, P. K., 1971, Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7, J. Infect. Dis. 124:155–160.

    Article  PubMed  Google Scholar 

  123. Gu, S., Huang, T., Ruan, L., Miao, Y., Lu, H., Chu, C. M., Motz, M., and Wolf, H., 1993, On the first EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen, In: Epstein-Barr Virus and Associated Disease (T. Tursz, J. S. Pagano, D. V. Ablashi, G. de Thé, G. Lenoir, and G. R. Pearson, eds.), Libbey, London/INSERM, Paris, pp. 579–584.

    Google Scholar 

  124. Gu, S., Huang, T., Miao, Y., Ruan, L., Zhao, Y., Han, C., Xiao, Y., Zhu, J., and Wolf, H., 1991, A preliminary study on the immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen, Chin. Med. Sci. J. 6:241–243.

    PubMed  CAS  Google Scholar 

  125. Moss, B., 1991, Vaccinia virus: A tool for research and vaccine development, Science 252:1662–1667.

    Article  PubMed  CAS  Google Scholar 

  126. Moss, B., Smith, G. L., Gerin, J. L., and Purcell, R. H., 1984, Live recombinant vaccinia virus protects chimpanzees against hepatitis B, Nature 311:67–69.

    Article  PubMed  CAS  Google Scholar 

  127. Bejarano, M. T., Masucci, M. G., Morgan, A. J., Morein, B., Klein, G., and Klein, E., 1990, Epstein-Bar virus (EBV) antigens processed and presented by B cells, B blasts and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation, J. Virol. 64:1398–1401.

    PubMed  CAS  Google Scholar 

  128. Lee, S. P., Wallace, L. E., Mackett, M., Arrand, J. R., Searle, P. F., Rowe, M., and Rickinson, A. B., 1993, MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways, Int. Immunol. 5:451–460.

    Article  PubMed  CAS  Google Scholar 

  129. Khyatti, M., Patel, P. C., Stefanescu, I., and Menezes, J., 1991, Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity, J. Virol. 65:996–1001.

    PubMed  CAS  Google Scholar 

  130. Finerty, S., Scullion, F. T., and Morgan, A. J., 1988, Demonstration in vitro of cell-mediated immunity to Epstein-Barr virus in cottontop tamarins, Clin. Exp. Immunol. 73:181–185.

    PubMed  CAS  Google Scholar 

  131. Qualtière, L. F., Decoteau, J. F., and Hassan Nasr-el-Din, M., 1987, Epitope mapping of the major Epstein-Barr virus outer envelope glycoprotein gp350/220, J. Gen. Virol. 68:535–543.

    Article  PubMed  Google Scholar 

  132. Cwirla, S. E., Peters, E. A., Barrett, R. W., and Dower, W. J., 1990, Peptides on phage: A vast library of peptides for identifying ligands, Proc. Natl. Acad. Sci. USA 87:6378–6382.

    Article  PubMed  CAS  Google Scholar 

  133. Geysen, H. M., Rodda, S. J., and Mason, T. J., 1986, A priori delineation of a peptide which mimics a discontinuous antigenic determinant, Mol. Immunol. 23:709–715.

    Article  PubMed  CAS  Google Scholar 

  134. Scott, J. K., and Smith, G. P., 1990, Searching for peptide ligands with an epitope library, Science 249:386–390.

    Article  PubMed  CAS  Google Scholar 

  135. Bancherau, J., and Rousset, F., 1991, Growing human B lymphocytes in the CD40 system, Nature 353:678–679.

    Article  Google Scholar 

  136. Bancherau, J., de Paoli, P., Valle, A., Garcia, E., and Rousset, E, 1991, Long-term human B cell lines dependant on interleukin 4 and antibody to CD40, Science 251:70–72.

    Article  Google Scholar 

  137. Khanna, R., Burrows, S. R., Suhrbier, A., Jacob, C.A., Griffin, H., Misko, I. S., Sculley, T. B., Rowe, M., Rickinson, A. B., and Moss, D. J., 1993, EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt’s lymphoma cells. Evidence for a critical role for ICAM-2, J. Immunol. 150:5154–5162.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Microbiology, School of Medical Sciences, University of Bristol, Bristol, BS8 1TD, England

    Andrew J. Morgan

Authors
  1. Andrew J. Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Microbiology, School of Medicine, University of Ferrara, I-44100, Ferrara, Italy

    Giuseppe Barbanti-Brodano

  2. University of Pisa, Pisa, Italy

    Mauro Bendinelli

  3. University of South Florida, Tampa, Florida, USA

    Herman Friedman

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer Science+Business Media New York

About this chapter

Cite this chapter

Morgan, A.J. (1995). The Development of Epstein-Barr Virus Vaccines. In: Barbanti-Brodano, G., Bendinelli, M., Friedman, H. (eds) DNA Tumor Viruses. Infectious Agents and Pathogenesis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1100-1_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-1100-1_21

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-1102-5

  • Online ISBN: 978-1-4899-1100-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation